跳至主要内容
临床试验/NCT02043925
NCT02043925已完成不适用

QT-prolongation in Psychiatric Hospitals

KU Leuven1 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
KU Leuven
入组人数
152
试验地点
1
主要终点
change in QTc-interval (corrected for heart rate)

研究概览

简要总结

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • inpatient in one of the 6 participating psychiatric hospitals
  • QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug

排除标准

  • age < 18 year

研究组 & 干预措施

psychiatric patients treated with QT-prolonging drugs

干预措施: drugs linked with QT-prolongation (Drug)

结局指标

主要结局

change in QTc-interval (corrected for heart rate)

时间窗: before and one week after the start of a QT-prolonging drug

次要结局

未报告次要终点

研究者

发起方
KU Leuven
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eline Vandael

PhD-student

KU Leuven

研究点 (1)

Loading locations...

相似试验